NCT07548918 Minoxidil Vitiligo Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07548918 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 3 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07548918 is a hot trial to watch
Vitiligo is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07548918 is notable because it evaluates Minoxidil in a Phase 2 design sponsored by Sohag University. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07548918 |
| Official title | Comparative Study of Microneedling With Topical Minoxidil 5% ± NB-UVB in Stable Vitiligo" |
| Phase / status | Phase 2 / Not yet recruiting |
| Intervention | Minoxidil |
| Sponsor | Sohag University |
| Geography | Not reported in the indexed record |
| Enrollment | [object Object] |
| Primary endpoint | Repigmentation in the vitiliginous area after receiving the treatment and increasing the wnt b catenin marker level in the histopathological specimen |
| Endpoint time frame | From enrollment to the end of treatment at 16 weeks for each patient |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
This study is a randomized controlled trial comparing microneedling with topical minoxidil 5% versus microneedling with minoxidil combined with NB-UVB phototherapy in stable vitiligo. It aims to evaluate both clinical and histopathological outcomes in 30 patients with non-segmental stable vitiligo. Vitiligo is a chronic depigmenting disorder caused by melanocyte destruction with significant psychosocial impact. The study also investigates immunohistochemical changes, particularly Wnt/β-catenin signaling expression in lesional skin. The combination therapy is expected to enhance repigmentation by improving melanocyte activation, drug delivery, and angiogenesis
Allocation is Randomized, masking is Double, and the intervention model is Factorial Assignment. Planned enrollment of [object Object] participants across Not reported in the indexed record shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Repigmentation in the vitiliginous area after receiving the treatment and increasing the wnt b catenin marker level in the histopathological specimen (From enrollment to the end of treatment at 16 weeks for each patient)
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Minoxidil is indexed as Small molecule drug, with target ABCC9 x Kir6.2, mechanism ABCC9 agonists, Kir6.2 agonists, and global highest development status Approved.
Company & Deal Intelligence MCP profile: Sohag University is resolved to a normalized organization record in Egypt. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07548918 provides a focused lens on Vitiligo development. Its value will be determined by whether Minoxidil can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
